|
Non-alcoholic Fatty Liver Disease
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the impact of the rs17618244 G>A β-Klotho (KLB) variant on liver damage in 249 pediatric patients with biopsy-proven NAFLD and the association of this variant with the expression of hepatic and soluble KLB.
|
31655133 |
2020 |
|
Non-alcoholic Fatty Liver Disease
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
<i>KLB</i> rs7674434 and rs12152703 had associations with alanine aminotransferase (ALT) (<i>P</i> = 0.03 and <i>P</i> = 0.04, respectively) and gamma-glutamyltransferase (<i>P</i> = 0.03 and <i>P</i> = 0.02, respectively) levels in all subjects, but the associations were especially strong with ALT in the NAFLD group (<i>P</i> = 0.005 and <i>P</i> = 0.008, respectively).
|
31548436 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.320 |
Biomarker
|
disease |
CTD_human |
Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease.
|
29289645 |
2018 |
|
Congenital hypogonadotropic hypogonadism
|
0.310 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
KLB, encoding β-Klotho, is mutated in patients with congenital hypogonadotropic hypogonadism.
|
28754744 |
2017 |
|
Congenital hypogonadotropic hypogonadism
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
<i>KLB</i>, encoding β-Klotho, is mutated in patients with congenital hypogonadotropic hypogonadism.
|
28754744 |
2017 |
|
Congenital hypogonadotropic hypogonadism
|
0.310 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Nonalcoholic Steatohepatitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease.
|
29289645 |
2018 |
|
Blood urea nitrogen measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A catalog of genetic loci associated with kidney function from analyses of a million individuals.
|
31152163 |
2019 |
|
Obesity
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The G-allele frequency of <i>KLB</i> rs7674434 and T-allele frequency of rs12152703 were higher in the obese with NAFLD than obese without NAFLD group (<i>P</i> = 0.004 and <i>P</i> = 0.006), but the genotype distribution between two non-obese groups did not differ.
|
31548436 |
2019 |
|
Uric acid measurement (procedure)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels.
|
31578528 |
2019 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Since obesity has been reported to be associated with reduced expression of FGFR1 and βKlotho receptor in white adipose tissues in mice, our results suggest that the distribution in adipose tissues was influenced by target expression levels.
|
28895785 |
2018 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Replenishment of recombinant FGF21 to a level equivalent to that in obesity restores SAT mass and reverses insulin resistance in FGF21KO, but not in adipose-specific βklotho knockout mice.
|
29348470 |
2018 |
|
Alcohol consumption
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic contributors to variation in alcohol consumption vary by race/ethnicity in a large multi-ethnic genome-wide association study.
|
28485404 |
2017 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
KLB and FGFR1 were upregulated in AT in relation to obesity, and both were further increased 12 months after RYGB.
|
28552744 |
2017 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In WAT, overweight/obesity with and without type 2 diabetes led to reduced expression of KLB, but increased FGFR1c expression.
|
28721439 |
2017 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
β-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue.
|
28422755 |
2017 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition to higher FGF21 levels, reduced KLB expression in liver and adipose tissue has been noted in these same individuals, suggesting that obesity may represent an FGF21 resistant state.
|
26901091 |
2016 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent microRNA (miR) studies have revealed that aberrantly elevated miR-34a in obesity directly targets β-Klotho, the obligate coreceptor for both FGF19 and FGF21, and attenuates metabolic signaling of these hormones.
|
27125742 |
2016 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, further studies are needed to explore the possibility that Klotho could be a novel therapeutic target to reduce obesity and related complications, and to determine whether and how Klotho might influence the regulation and function of a related protein, β-Klotho, which is also involved in energy metabolism.
|
22641000 |
2012 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that aberrantly elevated miR-34a in obesity attenuates hepatic FGF19 signaling by directly targeting βKL.
|
22988100 |
2012 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
To understand the role of FGF21 in regulating tumor aggressiveness in thyroid cancer, serum levels of FGF21 were measured in healthy subjects and patients with papillary thyroid cancer (PTC), and expression levels of FGF21, FGF receptors (FGFRs), and β-klotho (KLB) were investigated in human thyroid tissues.
|
31408968 |
2019 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
In conclusion, βKlotho inhibits EMT and plays a tumor‑suppressive role in PCa, linking FGF/FGFR/βKlotho signaling to the regulation of PCa progression.
|
29749458 |
2018 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
In discovery cohort 1, FGFR1 and Klotho beta (KLB) overexpression was associated with low tumor stage (P < 0.05), low tumor grade (P < 0.05), and better overall survival.
|
30593273 |
2018 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
AAV-NT mice also expressed increased levels of E-cadherin and fibroblast growth factor 21 (FGF21), targets of sirtuin-1, and β-klotho, which can acts as a tumor suppressor.
|
28334808 |
2017 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
KLB interacts with FGFR4 to induce apoptosis and inhibit the proliferation of hepatoma cells, and KLA has been demonstrated to be a tumor suppressor in human breast cancer; however, little is known regarding the role of KLB in breast cancer.
|
29344186 |
2017 |